DermConsult: Recent Episodes
ReachMD
There’s a lot dermatology specialists need to consider when ensuring patients have healthy skin. And at a time when clinical research is increasingly defining skin conditions—and the practice of dermatology itself—as “more than skin deep,” turn to DermConsult. Here dermatology specialists share their expert advice on the diagnosis and treatment of a variety of skin conditions. They also explore the latest clinical research and their very own case studies, so you can rest assured you’ll have access to everything you need to know about the body’s largest organ.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Steven R. Feldman, MD, PhD
Patients’ adherence to psoriasis treatment, especially topical treatment, is often abysmal due to a variety of challenges and factors. That’s why Dr. Charles Turck speaks with Dr. Steven Feldman about these common challenges and how we can overcome them to improve adherence among our psoriasis patients. Dr. Feldman is a Professor of Dermatology, Pathology, Social Sciences, and Health Policy at the Wake Forest University School of Medicine in Winston Salem, North Carolina.
Host: Raj Chovatiya, MD, PhD
Guest: Tina Bhutani, MD, MAS
Oftentimes patients with skin of color are diagnosed with psoriasis at a later stage than Caucasian patients. There are also disparities in access to treatment and education. According to a recent study, some patients with skin of color were less willing to use certain medications to treat their psoriasis. To learn more, join Dr. Raj Chovatiya and Dr. Tina Bhutani, Associate Adjunct Professor of Dermatology at the University of California San Francisco School of Medicine and Owner of Synergy Dermatology in San Francisco.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Amy McMichael, MD
A recent study that looked at psoriasis in patients from different races and backgrounds found that there weren’t a significant number of differences in the factors studied between patients with skin of color and Caucasian patients. The one thing that was really quite impactful for patients who are Black is that they wanted to see more physicians who could speak to their cultural and ethnic backgrounds. So to learn more about the findings and how we can address these barriers, join Dr. Charles Turck as he dives in with Dr. Amy McMichael, Professor in the Department of Dermatology at Wake Forest School of Medicine in Winston-Salem, North Carolina.
Guest: Andres Yarur, MD
It’s not uncommon for patients with inflammatory bowel disease (IBD) to have an overlapping immune-mediated condition like psoriasis, which is why it’s important to tailor therapy for these patients. Here to discuss the link between psoriasis and IBD and how this can affect our management approach is Dr. Andres Yarur, Associate Professor of Medicine at Cedars Sinai Medical Center in Los Angeles, California.
Guest: John Barbieri, MD, MBA, FAAD
Patients with psoriasis die about five years younger than those without the condition, and cardiovascular disease is the leading cause of this premature mortality. Tune in to hear Dr. John Barbieri discuss strategies to identify risk factors and improve cardiovascular disease prevention in patients with psoriasis. Dr. Barbieri is an Assistant Professor of Dermatology at Brigham and Women's Hospital at Harvard Medical School in Boston.
Host: Raj Chovatiya, MD, PhD
Guest: Jason E. Hawkes, MD, MS, FAAD
There are a few key points that dermatologists need to keep at the forefront of conversations to help bridge education gaps around psoriasis. One is to try and eliminate burdens that are deterring practitioners in dermatology from using highly effective and very safe medications. To learn more on how we can have a positive impact on education gaps and advocacy, join Dr. Raj Chovatiya as he speaks with Dr. Jason Hawkes, Medical Dermatologist in Sacramento, California.
Guest: Shari Lipner, MD
A recent study was conducted looking at initial therapies for newly diagnosed psoriasis patients by race. Prior studies have shown differences by race in terms of emerging treatments for different dermatological diseases, which have also shown differential biologic treatments based on race. To learn about the findings and how we can help fill this gap, join Dr. Shari Lipner, Associate Professor of Clinical Dermatology at Weill Cornell Medicine and co-author of the article, titled Racial Disparities in Primary Therapy for Newly Diagnosed Psoriasis Patients, which was published in the Journal of Drugs in Dermatology in July 2023.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Neda Shahriari, MD
This study assessed the link between depressive symptoms in real-world patients with psoriasis to help identify characteristics for those at risk. What were the findings? To learn more, join Dr. Charles Turck as he speaks with Dr. Neda Shahriari, Board-Certified Dermatologist at Brigham and Women’s Hospital in Boston, Massachusetts.
Host: Raj Chovatiya, MD, PhD
Guest: Steven R. Feldman, MD, PhD
To gain a better understanding of the different treatment attributes that patients with moderate-to-severe atopic dermatitis value most, a discrete choice experiment was conducted. And now, the results are in, with itch control being the top attribute. Joining Dr. Raj Chovatiya to share this and other key findings from his research that was featured as a poster at the 2023 Fall Clinical Dermatology conference is Dr. Steven Feldman, Professor of Dermatology, Pathology, Social Sciences, and Health Policy at the Wake Forest University School of Medicine in Winston-Salem, North Carolina.
Host: Raj Chovatiya, MD, PhD
Guest: Melinda Gooderham, MSc, MD, FRCPC
Due to the evolving treatment landscape, the way we think about treating adult and elderly patients with atopic dermatitis has shifted. So what are some special considerations we need to think about when selecting a treatment option for long-term control, and how can we best involve patients in the decision-making process? Joining Dr. Raj Chovatiya to help answer these and other key questions in atopic dermatitis care is Dr. Melinda Gooderham, Medical Director for the SKiN Center for Dermatology in Peterborough, Ontario.
Host: Raj Chovatiya, MD, PhD
Guest: Steven R. Feldman, MD, PhD
The biologics we know are revolutionary treatments for our patients with psoriasis and now other inflammatory skin diseases. So how do biosimilars play a part in the evolving treatment of psoriasis? Learn more with Dr. Raj Chovatiya as he dives further into biosimilars with Dr. Steve Feldman, Professor of Dermatology, Pathology, Social Sciences, and Health Policy at the Wake Forest University School of Medicine in Winston-Salem, North Carolina.
Host: Raj Chovatiya MD, PhD
Guest: George Han, MD, PhD
The discovery of the IL-23 pathway has revolutionized the treatment of psoriasis. Learn more about the current state of IL-23 inhibition in psoriasis management with Dr. Raj Chovatiya and Dr. George Han, Associate Professor in the Department of Dermatology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell in Uniondale, New York.
Host: Raj Chovatiya MD, PhD
Guest: Jennifer Soung, MD
Guest: Einjuan James Song, MD, FAAD
The atopic dermatitis treatment landscape has evolved over the past several years. To catch up on the current treatment options available and the novel therapies in development, Dr. Raj Chovatiya speaks with Drs. James Song and Jennifer Soung. Dr. Song is the Director of Clinical Research for Frontier Dermatology Partners in Everett, Washington, and Dr. Soung is the Director of Clinical Research at Southern California Dermatology in Santa Ana, California.
Host: Raj Chovatiya MD, PhD
Guest: Matthew Zirwas, MD
Guest: Douglas DiRuggiero, DMSc, PA-C
When managing atopic dermatitis, it’s up to the patient to determine how much therapeutic intervention they want to pursue, which underscores the importance of applying shared decision-making to practice. Joining Dr. Raj Chovatiya to share their perspectives on how we can utilize shared decision-making in atopic dermatitis care are Dr. Matthew Zirwas and Mr. Douglas DiRuggiero. Dr. Zirwas founded Bexley Dermatology Research Clinic in Columbus, Ohio where he specializes in adult eczema, and Mr. DiRuggiero is a certified physician assistant at the Skin Cancer and Cosmetic Dermatology Center in Rome, Georgia.
Host: Raj Chovatiya MD, PhD
Guest: George Han, MD, PhD
Our understanding of TYK2’s role in the pathophysiology of psoriasis has recently evolved, leading to new treatment options like deucravacitinib. Deucravacitinib is the first approved TYK2 inhibitor approved for moderate to severe plaque psoriasis. Learn more about this treatment option and the role of TYK2 with Dr. Raj Chovatiya and Dr. George Han, Associate Professor in the Department of Dermatology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell in Uniondale, New York.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Jonathan Silverberg, MD, PhD, MPH
Atopic dermatitis is more than a disease of the skin. It’s a complex and heterogeneous inflammatory disease mediated by multiple T-cell–driven inflammatory pathways, like the OX40 pathway, leading to chronic and persistent symptoms and significant burden.1-4 Explore the heterogeneity of atopic dermatitis and the importance of OX40 signaling in disease pathogenesis with Dr Charles Turck and Dr. Jonathan Silverberg, Professor and Director of Clinical Research and the Director of Patch Testing at George Washington University School of Medicine and Health Sciences.
References:
- Silverberg JI. Clinical Management of Atopic Dermatitis. 1st ed. 2018.
- Ratchataswan T, et al. J Allergy Clin Immunol Pract. 2021;9:1053-1065.
- Weidinger S, et al. Nat Rev Dis Primers. 2018;4:1.
- De Bruyn Carlier T, et al. J Autoimmun. 2021;120:102634.
©2023 Amgen Inc. All rights reserved. USA-451-80031 8/23
Host: Raj Chovatiya MD, PhD
Guest: Jason E. Hawkes, MD, MS, FAAD
Generalized pustular psoriasis is a rare inflammatory skin disease that can be life-threatening if left untreated, and treatment typically involves the use of therapies approved for plaque psoriasis. However, that could all be changing thanks to the recent understanding of IL-36’s role in generalized pustular psoriasis and the development of the treatment option spesolimab. Learn more with Dr. Raj Chovatiya and Dr. Jason Hawkes, medical dermatologist in the Greater Sacramento area who also sits on the National Psoriasis Foundation Medical Board and Scientific Advisory Committee.
Host: Raj Chovatiya MD, PhD
Guest: Jason E. Hawkes, MD, MS, FAAD
Roflumilast and tapinarof are two of the new topical nonsteroidal therapies for plaque psoriasis that have several advantages over the traditional topical steroids. Learn more about how emerging topical nonsteroidals could impact your patients with plaque psoriasis with Dr. Raj Chovatiya and Dr. Jason Hawkes, a medical dermatologist in the Greater Sacramento area who also sits on the National Psoriasis Foundation Medical Board and Scientific Advisory Committee.
Host: Jason J. Luke, MD, FACP
Guest: Tara Mitchell, MD
The 5-year recurrence rates for stage IIB and IIC melanoma are up to 46%, but now new immunotherapy options are FDA-approved for the adjuvant treatment of stage IIB and IIC melanoma. Find out why this matters and hear Drs. Jason Luke and Tara Mitchell break down the latest data on treating stage IIB and IIC melanoma with adjuvant immunotherapy.
Host: Raj Chovatiya MD, PhD
Guest: Martina J. Porter, MD
Two of the biggest trials were recently completed for the use of IL-17 inhibitors for treating hidradenitis suppurative (HS). So what data should we know about? In this episode, Dr. Raj Chovatiya is joined by Dr. Martina Porter, Dermatologist at Beth Israel Deaconess Medical Center and Assistant Professor of Dermatology at Harvard Medical School.
Host: Raj Chovatiya MD, PhD
Guest: Martina J. Porter, MD
For patients with hidradenitis suppurativa (HS) the exact cause of the condition is still being researched. So what therapies are currently available to treat this painful condition? To discuss what you need to know, Dr. Raj Chovatiya is joined by Dr. Martina Porter, Dermatologist at Beth Israel Deaconess Medical Center and Assistant Professor of Dermatology at Harvard Medical School.
Host: Raj Chovatiya MD, PhD
Guest: Britt Craiglow, MD
The future looks promising for alopecia areata patients as two JAK inhibitors have been tested in clinical trials while other treatment studies are ongoing. So what should clinicians know about these therapies? Learn more as Dr. Raj Chovatiya speaks to Dr. Britt Craiglow, Adjunct Associate Professor at the Yale School of Medicine and Double Board-Certified Dermatologist with Dermatology Physicians of Connecticut.
Host: Raj Chovatiya MD, PhD
Guest: Britt Craiglow, MD
Initially approved for the treatment of rheumatoid arthritis, baricitinib is now the first FDA-approved treatment for patients with alopecia areata. So what can patients look forward to with this new therapy? Dive in with Dr. Raj Chovatiya as he’s joined by Dr. Britt Craiglow, Adjunct Associate Professor at the Yale School of Medicine and Double Board-Certified Dermatologist at Dermatology Physicians of Connecticut.
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Justin Cheeley, MD
Proper access to medication can present challenges for the doctor and patient but is necessary to achieve optimal patient outcomes. So how can they work together to eliminate this burden? To discuss this further, Dr. Mary Katherine Cheeley is joined by Dr. Justin Cheeley, Assistant Professor in the Departments of General Internal Medicine and Dermatology and the Director of Inpatient Dermatology at Emory School of Medicine.
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Justin Cheeley, MD
Patients with IBD, arthritis, or other disorders of the immune system may be at a higher risk for developing pyoderma gangrenosum (PG). So how can clinicians better manage their patients with PG? Explore this rare condition as Dr. Mary Katherine Cheeley is joined by Dr. Justin Cheeley, Assistant Professor in the Departments of General Internal Medicine and Dermatology and the Director of Inpatient Dermatology at the Emory School of Medicine.
Host: Matthew S. Keller MD
Host: Monica Schwartzman, MD, MS
Getting the proper treatment for patients with psoriasis and psoriatic arthritis can be life-changing. So how can clinicians help patients find the right medication? To discuss this topic together, Dr. Matthew Keller is joined by fellow ReachMD host, Dr. Monica Schwartzman, who is also a Rheumatologist.
Host: Michael Greenberg, MD
Guest: Jonathan S. Weiss, MD
Physician assistants (PAs) are licensed to practice medicine to provide many of the same services as a physician. And they may even train in dermatology. But what do we need to take into consideration when bringing a PA into a dermatology practice? Joining Dr. Michael Greenberg to discuss the ethics of this all-too-common situation is Dr. John Weiss, President and Co-Managing Partner at Georgia Dermatology Partners.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Natasha Mesinkovska, MD, PhD
Alopecia areata is an autoimmune condition with a complex pathophysiology. That’s why Dr. Charles Turck speaks with Dr. Natasha Mesinkovska from the University of California, Irvine about the pathophysiology of alopecia areata and how its underlying mechanisms impact what we see in practice.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Arash Mostaghimi, MD, MPA, MPH
Key assessments like the Severity of Alopecia Tool and the Alopecia Areata Investigator Global Assessment tool can help us assess the severity and impact of alopecia areata on our patients. Joining Dr. Charles Turck to discuss how we can implement these tools into practice is Dr. Arash Mostaghimi, Assistant Professor at Harvard Medical School and Director of the Dermatology Inpatient Service at Brigham and Women’s Hospital in Boston.
Guest: Natasha Mesinkovska, MD, PhD
Given the rising prevalence of alopecia areata, what do we need to know about patients’ unmet needs? And what are the barriers clinicians face when managing patients? Here to talk about alopecia areata is Dr. Natasha Mesinkovska, Associate Professor and Vice Chair for Clinical Research in the Dermatology School of Medicine at the University of California Irvine.
Host: Matthew S. Keller MD
Guest: Natasha Mesinkovska, MD, PhD
Alopecia areata affects more than 300,000 people in the United States each year, causing hair loss to the scalp, eyebrows, and eyelashes. But recent studies have shown that the Janus kinase inhibitor drug baricitinib can help significantly regrow hair for patients. To find out more about what this first-ever FDA approval of a systemic treatment could mean for patients with alopecia areata, Dr. Matthew Keller speaks with Dr. Natasha Mesinkovska, Associate Professor of Dermatology and Vice Chair for Clinical Research of Dermatology at University of California Irvine.
Host: Michael Greenberg, MD
Guest: Lynn McKinley-Grant, MD, FAAD
Psoriatic disease looks and feels different for people of color, and these differences may affect their diagnosis, treatment, and—by extension—quality of life. In fact, more than 50 percent of people with psoriatic arthritis experience a 2-year delay in diagnosis and a lower quality of life compared to white patients. So how can we help close the diagnostic gap and provide better care for our patients of color with psoriatic arthritis? To find out, Dr. Michael Greenberg is joined by Dr. Lynn McKinley-Grant, Associate Professor of Dermatology at Howard University College of Medicine.
Host: Michael Greenberg, MD
Guest: Esther Freeman, MD, PhD
Guest: Steven Chen, MD, MPH, MHPEd
With the recent rise of monkeypox cases around the world, dermatologists will be some of the first to evaluate and diagnose patients with the disease. So to help those on the frontlines, Dr. Esther Freeman, Director of Global Health Dermatology at Massachusetts General Hospital and Dr. Steven Chen, Assistant Professor of Dermatology at Harvard Medical School, share what dermatologists need to know about monkeypox.
Host: Michael Greenberg, MD
Guest: Brook Brouha, MD, PhD
How might genomics help us provide better care for our patients? Joining Dr. Michael Greenberg to share how he’s utilizing genomics in practice is Dr. Brook Brouha, a dermatologist and dermatopathologist at West Dermatology in San Diego, California.
Host: Matthew S. Keller MD
Guest: Michael Greenberg, MD
Are you looking to increase business at your dermatology practice? One simple solution is practicing goodness—in other words, being good and kind to your patients and their families. Joining Dr. Matthew Keller to explain why goodness is the best practice builder is fellow ReachMD Host Dr. Michael Greenberg.
Host: Michael Greenberg, MD
Guest: Dustin Portela, DO
The prevalence of social media has grown significantly over the past few decades, and within the field of medicine, we’ve seen a rise in dermatologists using these platforms to grow their professional network, improve patient care, and provide essential education. But what ethical challenges arise from a widespread social media presence, and how can we navigate those challenges? To find out, Dr. Michael Greenberg speaks with Dr. Dustin Portela about his online presence as 208SkinDoc.
Host: Matthew S. Keller MD
Guest: Shawn Kwatra, MD
As the most common type of eczema, atopic dermatitis is a chronic, inflammatory skin disorder that affects millions of people worldwide. And although it’s a complex disease with no cure, the FDA recently approved two oral JAK-1 inhibitors for patients with mild-to-severe-symptoms. So what do we need to know about these new treatment options? Joining Dr. Matthew Keller to review the role of JAK inhibitors in atopic dermatitis is Dr. Shawn Kwatra, Associate Professor of Dermatology at Johns Hopkins University School of Medicine and Director of the Johns Hopkins Itch Center.
Host: Jane Mast, PA-C, MPAS, DMSc
Guest: Douglas DiRuggiero, DMSc, PA-C
Join podcast guest Doug DiRuggiero, PA, a certified physician assistant and the founding president of Georgia Dermatology Physician Assistant Society, and host Jane Mast, a Novartis Medical Director and certified physician assistant in a discussion focusing on the diagnosis and management of psoriasis in pediatric and adolescent patients.
During their discussion, they address the following topics:
- Important clinical features of psoriasis in children and adolescents and how they may differ from those in adult patients
- Communication strategies to use when talking to parents about their child’s psoriasis
- Psychosocial impact of psoriasis
- Approaches to management
This podcast is sponsored by Novartis Pharmaceuticals Corporation and the podcast guest is being compensated for his time.
© 2021 Novartis Pharmaceuticals Corporation
Host: Michael Greenberg, MD
Guest: Arash Mostaghimi, MD, MPA, MPH
Acne vulgaris is a common dermatologic condition with a variety of treatment options available. But due to its multifactorial pathogenesis and the limitations of current therapies, evolving treatments and management guidelines are needed. Fortunately, several therapies have emerged in recent years, so to learn more about what’s new in the treatment landscape, Dr. Michael Greenberg speaks with Dr. Arash Mostaghimi, Director of Dermatology Inpatient Service at Brigham and Women’s Hospital.
Host: Matthew S. Keller MD
Guest: Linda Stein Gold, MD
For many years, acne scarring was considered to be a result of severe acne, but recent research shows that scarring can affect any patient regardless of the severity. Additionally, acne scarring can significantly reduce a patient's quality of life, which is why it's important that treatment is started early to achieve better outcomes. So to help us gain a better understanding of the assessment and treatment strategies currently available, Dr. Matthew Keller speaks with Dr. Linda Stein Gold, Director of Dermatology Clinical Research at Henry Ford Health System in Detroit.
Host: Jennifer Caudle, DO
Guest: Melodie Young, MSN
Plaque psoriasis is canonically characterized by red, scaly, well demarcated plaques; however, the impact of this chronic systemic disease cannot be fully understood by the extent of skin involvement alone. Moderate psoriasis can have a large impact on patients due to factors such as involvement of special areas (such as the scalp) and persistent itching. Reaching a better understanding of these patients requires looking beyond skin involvement, assessing all aspects of disease, and considering patient perspectives.
Ms. Melodie Young, a Nurse Practitioner specialist of dermatology, joins Dr. Jennifer Caudle to give us deeper insight into this systemic disease, the potential impact on patients with moderate disease, and important aspects of psoriasis to consider in disease assessment.
USA-407-81472
Host: Michael Greenberg, MD
Host: Matthew S. Keller MD
As clinicians, we often need to address our patients’ emotional health just as much as their physical health, and bedside manner plays a big part in that. So to help ensure our patients are getting the most out of their visits, Drs. Matthew Keller and Michael Greenberg come together in this two-part discussion to share their tips for improving bedside manner.
Host: Michael Greenberg, MD
Host: Matthew S. Keller MD
How do you respond when your patient’s frustrations—and even perhaps your own—creep into a visit? And how can you incorporate professional intimacy into your practice? Find out in part 2 of Dr. Matthew Keller and Dr. Michael Greenberg’s discussion on how we can improve our bedside manner.
Host: Michael Greenberg, MD
Guest: Howard K. Steinman, MD
We always want patients to leave our office feeling happy, healthy, and pleased with their care, but unfortunately, that isn't always the case. The good news, however, is that the acronym BLAST can help guide our conversations with patients who are less than satisfied with their care. Joining Dr. Michael Greenberg to break down this five-step method for speaking with displeased patients is Dr. Howard Steinman, a board-certified dermatologist and fellow of the American College of Mohs Surgery.
Host: Michael Greenberg, MD
Guest: Robert T. Brodell, MD
As children, stories and fables capture our imaginations and even teach us some important life lessons, and our love of stories isn't necessarily something we grow out of. After all, as adults, we're constantly hearing news stories and catching the latest movies, podcasts, and shows. So might there be a role for storytelling in our visits with patients? To find out, Dr. Michael Greenberg speaks with Dr. Robert Brodell, Professor and Chair in the Department of Dermatology and Professor of Pathology at the University of Mississippi Medical Center.
Host: Matthew S. Keller MD
Guest: Omer Ibrahim, MD
In this episode, you’ll hear from board-certified dermatologist Dr. Omer Ibrahim about the rising prevalence of bed bug infestations, diagnostic and treatment strategies, and how we can help patients manage and prevent bed bug infestations.
Host: Michael Greenberg, MD
Guest: Joel Schlessinger, MD
Spa dermatology has morphed over the last 20 to 30 years, but not all of those changes benefited our patients. In fact, there are now several ethical and practical concerns when it comes to illegitimate med spas. Joining Dr. Matthew Keller to share those considerations and what we as dermatologists need to know so we can help guide our patients is board-certified dermatologist and cosmetic surgeon Dr. Joel Schlessinger.
Host: Michael Greenberg, MD
Guest: Sam Polesie, PhD
Can technology play a role in assessing melanoma? Dr. Michael Greenberg discusses the use of artificial intelligence in dermatology with Dr. Sam Polesie, a specialist physician in the Department of Dermatology and Venereology at the Sahlgrenska University Hospital in Gothenburg, Sweden.
Host: Michael Greenberg, MD
Host: Matthew S. Keller MD
Curious about the use of topical therapy to treat a variety of dermatological conditions like eczema and molluscum contagiosum? Here to share their experiences with topical therapy in clinical practice are ReachMD hosts Dr. Michael Greenberg and Dr. Matthew Keller.
Host: Michael Greenberg, MD
Guest: Svitlana Kurinna, PhD
What’s the latest research on skin regeneration, and how might it influence the regeneration of other tissues and organs? Joining Dr. Michael Greenberg to answer that question based on data from her recent study focusing on how the skin repairs itself is Dr. Svitlana Kurinna, a research fellow in the Division of Cell Matrix Biology and Regenerative Medicine at the University of Manchester.
Host: Matthew S. Keller MD
Guest: Maria L. Wei MD, PhD
Wildfires are most often associated with respiratory and cardiovascular health threats, but could they also affect the skin? That’s the exact question dermatologist and melanoma specialist Dr. Maria Wei sought to answer with her recent study and the one that she addresses with Dr. Matthew Keller.
Host: Michael Greenberg, MD
In honor of Skin Cancer Awareness Month, Dr. Michael Greenberg reflects on a close call one of his patients had with skin cancer and how that experience taught him the importance of trusting his patients’ intuitions and easing their fears.
Host: Michael Greenberg, MD
Guest: Peter B. Crino, MD, PhD
How does tuberous sclerosis impact patients? Dr. Michael Greenberg joins Dr. Peter Crino, the chair of the Department of Neurology at the University of Maryland School of Medicine, to discuss tuberous sclerosis complex, or TSC.